DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 15.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,608,475 shares of the medical device company’s stock after selling 997,212 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in DexCom were worth $377,394,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DXCM. Brighton Jones LLC lifted its position in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC raised its stake in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. Empowered Funds LLC lifted its position in DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares during the last quarter. Focus Partners Wealth boosted its stake in DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its stake in DexCom by 2.5% in the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 49,167 shares of the medical device company’s stock valued at $4,292,000 after acquiring an additional 1,183 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. JPMorgan Chase & Co. reduced their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research note on Friday, October 31st. BTIG Research decreased their price objective on DexCom from $109.00 to $85.00 and set a “buy” rating for the company in a report on Friday, October 31st. Leerink Partners reaffirmed an “outperform” rating and issued a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th. Finally, Royal Bank Of Canada reduced their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $86.30.

DexCom Trading Up 0.4%

NASDAQ:DXCM opened at $69.54 on Monday. The firm has a market cap of $27.12 billion, a P/E ratio of 38.63, a PEG ratio of 1.25 and a beta of 1.48. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The stock’s 50 day simple moving average is $65.03 and its 200-day simple moving average is $71.47. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the company earned $0.45 earnings per share. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity

In other news, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the purchase, the chief operating officer directly owned 331,697 shares in the company, valued at $18,256,602.88. The trade was a 5.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the transaction, the director directly owned 27,031 shares of the company’s stock, valued at $1,569,690.17. This represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,866 shares of company stock valued at $448,177 over the last quarter. Corporate insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.